Search filters

Filters
Clear All

Phase

  • 3
  • 3
  • 6
  • 1
  • 6

Found 6 Idiopathic Pulmonary Fibrosis trials

A listing of Idiopathic Pulmonary Fibrosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

99 years or below
All genders
This study is the OLE of the Main study currently ongoing. Targeted population are those individuals who completed the original study. Study procedures include physical exams, safety labs, ECGs, breathing tests, and questionnaires.
 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis
40 years - 99 years
All genders
This study is looking to see if inhaled treprostinil helps patients with IPF improve their pulmonary function tests. Patients will randomized to either placebo or inhaled treprostinil and will also undergo the following throughout the study: PFTs, physical exams, EKGs, HRCT, questionnaires, vital signs, lab tests
18 years - 99 years
All genders
This is a double-blind, placebo controlled study to assess the safety and efficacy of BI1015550 on patients with IPF. It is a phase 3 study and will including physical exams, a CT, questionnaires, safety lab samples, lung function testing, and ECGs.
 Visceral adipose tissue and frailty in idiopathic pulmonary fibrosis
18 years - 99 years
All genders
The research study is being conducted to better understand how fat and muscle are related to disability and health-related quality of life in people with idiopathic pulmonary fibrosis.
18 years - 80 years
All genders
The purpose of this study is to determine if the INOpulse® delivery system, that includes the INOpulse® device, inhaled nitric oxide study drug as delivered via triple lumen nasal cannula can help treat patients with fibrotic interstitial lung disease (fILD) who are on oxygen therapy and who are at risk …
18 years - 99 years
All genders
The aim of the pilot study is to demonstrate feasibility and tolerability of semaglutide in patients with obesity and advanced ILD.